Presence of calreticulin mutations in JAK2-negative polycythemia vera

Blood. 2014 Dec 18;124(26):3964-6. doi: 10.1182/blood-2014-06-583161. Epub 2014 Oct 10.

Abstract

Calreticulin (CALR) mutations have been reported in Janus kinase 2 (JAK2)- and myeloproliferative leukemia (MPL)-negative essential thrombocythemia and primary myelofibrosis. In contrast, no CALR mutations have ever been reported in the context of polycythemia vera (PV). Here, we describe 2 JAK2(V617F)-JAK2(exon12)-negative PV patients who presented with a CALR mutation in peripheral granulocytes at the time of diagnosis. In both cases, the CALR mutation was a 52-bp deletion. Single burst-forming units-erythroid (BFU-E) from 1 patient were grown in vitro and genotyped: the same CALR del 52-bp mutation was noted in 31 of the 37 colonies examined; 30 of 31 BFU-E were heterozygous for CALR del 52 bp, and 1 of 31 BFU-E was homozygous for CALR del 52 bp. In summary, although unknown mutations leading to PV cannot be ruled out, our results suggest that CALR mutations can be associated with JAK2-negative PV.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alleles
  • Calreticulin / genetics*
  • Erythrocytes / cytology
  • Exons
  • Gene Deletion
  • Genotype
  • Hemoglobins / chemistry
  • Heterozygote
  • Humans
  • Janus Kinase 2 / genetics*
  • Male
  • Mutation*
  • Polycythemia Vera / genetics*
  • Primary Myelofibrosis / genetics*
  • Thrombocythemia, Essential / genetics
  • Thrombocytosis / genetics*

Substances

  • Calreticulin
  • Hemoglobins
  • JAK2 protein, human
  • Janus Kinase 2